Figure 8

Levetiracetam as a potential neuroprotectant.

(A) Risk of death associated with levetiracetam (Lev) treatment of primary cortical neurons. 1–5 μM had no effect on baseline risk of death. N.S., not significant. Results were pooled from at least three independent experiments. (B) Quantification of fluorescent images of cortical cultures at 28–32 DIV treated with a vehicle or with 1–5 μM levetiracetam (Lev) for 3 days and stained with antibodies against synapsin and microtubule-associated protein, MAP2c. Synapsin staining was used by the algorithm to identify and analyze synapses. Cont., control. Levetiracetam, Lev. A.u., arbitrary units. N.S., not significant (t-test). (C) Quantification of fluorescent images from (C) with an algorithm that identifies and analyzes neurites based on MAP2c staining. Cont., control. Levetiracetam, Lev. A.u., arbitrary units. N.S., not significant (t-test).